Amphastar Pharmaceuticals (AMPH) Income from Continuing Operations (2013 - 2026)

Amphastar Pharmaceuticals' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 6420000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 74.61% year-over-year to 6420000.0 in Q1 2026; TTM through Mar 2026 was 102383000.0, a 27.71% decrease from a year earlier, with the FY2025 full-year figure at 121248000.0, down 24.26% from the prior year.
• Income from Continuing Operations retreated to 6420000.0 in Q1 2026 per AMPH's latest filing, from 47583000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 49612000.0 in Q3 2023 and bottomed at 145250000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 26817000.0 (2023), against an average of 19878058.82.
• Across the five-year window, Income from Continuing Operations surged 530.36% in 2022 and slumped 527.58% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 33970000.0 in 2022, then slumped by 527.58% to 145250000.0 in 2023, then soared by 126.14% to 37964000.0 in 2024, then grew by 25.34% to 47583000.0 in 2025, then slumped by 86.51% to 6420000.0 in 2026.
• Per Business Quant, the three latest AMPH Income from Continuing Operations figures stand at 6420000.0 (Q1 2026), 47583000.0 (Q4 2025), and 17350000.0 (Q3 2025).